Abstract:| https://dx.doi.org/10.21037/hbsn-21-392 Up to know, product information for COVID-19 mRNA vaccines do not include their use in patients receiving immunosuppressive medication, since they were not included in trials (1) . For the BNT162b2 mRNA vaccine, one case of otherwise totally asymptomatic elevations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (GGT) serum concentrations in a liver transplant recipient has been reported after the first injection (2). In the present retrospective study, we present safety outcomes of COVID-19 vaccinations in 56 liver transplant patients from two Chinese centers vaccinated with the domestic PiCoVacc, BBIBP-CorV and ZF2001 vaccines. Thirty vaccinated physicians from the Hepatopancreatobiliary Center of Beijing Tsinghua Changgung Hospital served as control, from which 1 participant received an Ad5-nCoV vaccine. The study deadline was 2021-10-31. The observation period for adverse reactions, such as muscle pain and fatigue was 1 week, while for laboratory examinations such as liver function the follow-up period was 1 month. PiCoVacc and BBIBP-CorV are both inactivated COVID-19 virus vaccines with a two-dose schedule and a spacing of 3 to 4 weeks, while ZF2001 is a recombinant tandem-repeat dimeric receptor-binding domain (RBD)based protein subunit vaccine with an application of three doses over a period of 2 months. Ad5-nCoV is a viral vector vaccine applied as a single injection. Table 1 shows the basic characteristics of the 86 participants. Adverse reactions in the liver transplant and control groups were fatigue (4, 7.1% vs. 1, 3.3%), local pain (9, 16.1% vs. 6, 20.0%), cough (1, 1.8% vs. 0), rhinorrhea (1, 1.8% vs. 0) and drowsiness (0 vs. 4, 13.3%), respectively. All adverse reactions were mild. Fifty-four participants had normal liver function tests within 1 month before and after vaccination. A 37-year-old patient, 70 months after transplantation due to a primary liver cancer who was receiving an antirejection regimen of sirolimus + mycophenolate mofetil (MMF), had liver enzyme values of ALT 72.0 U/L, AST 37.6 U/L, total bilirubin (TBIL) 13.7 μmol/L, ALP 80.0 U/L and GGT 58.3 U/L before and ALT 68.3 U/L, AST 37.7 U/L, TBIL 11.0 μmol/L, ALP 96.0 U/L and GGT 62.2 U/L after vaccination. The condition was considered to be related to the graft fatty liver and the liver function changes were not significant before and after vaccination. The second case was a 46-year-old patient with hepatic alveolar echinococcosis 30.7 months after transplantation and an anti-rejection regimen of tacrolimus + MMF. Liver enzyme values were ALT 22 U/L, AST 29 U/L, TBIL 12.4 μmol/L, ALP 134 U/L, GGT 44 U/L before and ALT 19 U/L, AST 25 U/L, TBIL 11 μmol/L, ALP 106 U/L and GGT 41 U/L after vaccination. The patient underwent a choledochojejunostomy, because of a narrow biliary anastomosis. Since there was no stenosis after the choledochojejunostomy, this abnormal ALP may be related to the state of bilioenteroanastomosis. Two of the vaccines in the present study were inactivated viruses, which are only recommended for solid organ transplant recipients after careful risk benefit assessment, Letter to the Editor

Gingivo-mucosal and cutaneous reactions to amalgam fillings.

High vaccination coverage and infection rate result in a robust SARS‐CoV‐2‐specific immunity in the majority of liver cirrhosis and transplant patients: A single‐center cross‐sectional study

Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis

Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

Immunogenicity and Safety of a Booster COVID-19 Vaccination in Patients with Chronic Liver Disease:A Multicenter Study

Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study

Clinical application of COVID-19 vaccine in liver transplant recipients

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Humoral and cellular immune response in patients of liver cirrhosis and immunocompetent recipient of ChAdOx1nCoV-19 Vaccine (Covishield)

Deficient Immune Response following SARS-CoV-2 Vaccination in Patients with Hepatobiliary Carcinoma: A Forgotten, Vulnerable Group of Patients

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study

COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study

Oxidative Stress Interferes With White Matter Renewal After Prolonged Cerebral Hypoperfusion in Mice

Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico

Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study

Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota

Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease

Safety Analysis of COVID-19 Vaccines in Liver Transplant Recipients: a Two-Center Study.

Mucilaginibacter rubeus sp. nov., isolated from rhizosphere soil.